-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CQeNm6PtnAkQ/gziGid1PoNoe1ftxdarPOVe4SHjW9EAgt9kQ936ObQzqv7QnIQP
 nRXdvu01P4VMIictAPYTMg==

<SEC-DOCUMENT>0000950123-07-012543.txt : 20070912
<SEC-HEADER>0000950123-07-012543.hdr.sgml : 20070912
<ACCEPTANCE-DATETIME>20070912140016
ACCESSION NUMBER:		0000950123-07-012543
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20070912
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20070912
DATE AS OF CHANGE:		20070912

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC/NJ
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		071112833

	BUSINESS ADDRESS:	
		STREET 1:		220 S ORANGE AVE
		STREET 2:		LIVINGSTON CORPORATE PARK
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		2013793171

	MAIL ADDRESS:	
		STREET 1:		44 KEAN ROAD
		STREET 2:		220 SOUTH ORANGE AVE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y39605e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>






<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<DIV align="center">
<DIV style="font-size: 3pt; margin-top: 16pt; width: 26%; border-top: 1px solid #000000">&nbsp;</DIV>
</DIV>



<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported) </B><U><B>September&nbsp;12, 2007</B></U></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B><FONT style="border-bottom: 1px solid #000000">MILESTONE SCIENTIFIC INC.</FONT></B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of Registrant as specified in its charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-26284</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>13-3545623</B></TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>(State or other <BR>
jurisdiction of <BR>
incorporation)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(Commission File<BR>
Number)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>(IRS Employer<BR>
Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><FONT style="border-bottom: 1px solid #000000"><B>220 South Orange Avenue, Livingston Corporate Park, Livingston, New Jersey 07034</B></FONT><BR>
<B>(Address of principal executive office) (Zip Code)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Registrant&#146;s telephone number, including area code </B><FONT style="border-bottom: 1px solid #000000"><B>(973)&nbsp;535-2717</B></FONT></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>N/A<BR>
<DIV style="margin-top: 1px"><FONT style="border-top: 1px solid #000000">(Former name or former address, if changed since last report)</B></FONT></DIV></DIV>

<!-- &nbsp; -->
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">








<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;5.02:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Effective September&nbsp;12, 2007, Thomas R. Ronca resigned from his employment with and his
position as Chief Operating Officer and President of Milestone.
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;8.01:</B></TD>
    <TD>&nbsp;</TD>
    <TD><B>Other Matters.</B></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;12, 2007, Milestone issued a press release announcing the commencement of a
Declaratory Judgment Action against Milton Hodosh, DMD on August&nbsp;24, 2007 in the United States
District Court of New Jersey seeking a determination by that Court that neither Milestone&#146;s <I>Single
Tooth Anesthesia (STA</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP>) system nor its <I>CompuDent</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP> system infringed claims set
forth in United States Patent No.&nbsp;6159161 filed by Dr.&nbsp;Hodosh on July&nbsp;8, 1998 and issued by the
United States Patent Office on December&nbsp;12, 2000, and also announcing the subsequent commencement
of an infringement action by Dr.&nbsp;Hodosh.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A copy of the Press Release is furnished as Exhibit&nbsp;99.1 hereto.
</DIV>

<DIV align="left" style="margin-top: 12pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; background: transparent; color: #000000">
<TR>
    <TD width="3%"></TD>
    <TD width="1%"></TD>
    <TD></TD>
</TR>
<TR valign="top">
    <TD nowrap align="left"><B>Item&nbsp;9.01:</B></TD>
    <TD>&nbsp;</TD>
    <TD><U><B>Financial Statements and Exhibits</B></U></TD>
</TR>
</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 10%">(d)&nbsp;Exhibits:
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="14%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left">99.1</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Press Release dated September&nbsp;12, 2007.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left"><B>MILESTONE SCIENTIFIC INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Leonard Osser
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Leonard Osser&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chairman and Chief Executive Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dated: September&nbsp;12, 2007
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y39605exv99w1.htm
<DESCRIPTION>EX-99.1: PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="y39605y3960501.gif" alt="(MILESTONE SCIENTIFIC LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MILESTONE SCIENTIFIC COMMENCES DECLARATORY JUDGMENT<BR>
ACTION WITH RESPECT TO ITS SINGLE TOOTH ANESTHESIA (STA</B><SUP style="font-size: 85%; vertical-align: text-top"><B>&#153;</B></SUP><B>)<BR>
SYSTEM AND </B><B><I>COMPUDENT</I></B><SUP style="font-size: 85%; vertical-align: text-top"><B>&#153;</SUP> SYSTEM</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B><I>Defendant Brings Infringement Action</I></B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>LIVINGSTON, N.J. &#151; (PR NEWSWIRE) &#151; September&nbsp;12, 2007 </I></B>&#151; Milestone Scientific, Inc.
(OTCBB:MLSS) today announced that on August&nbsp;24, 2007 it commenced a Declaratory Judgment Action
against Milton Hodosh, DMD in the United States District Court for the District of New Jersey
seeking a determination by that Court that neither its <I>Single Tooth Anesthesia (STA</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP>)
system nor its <I>CompuDent</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP> system infringed claims set forth in United States Patent No.
6159161 filed by Dr.&nbsp;Hodosh on July&nbsp;8, 1998 and issued by the United States Patent Office on
December&nbsp;12, 2000. Milestone&#146;s basic patents covering these systems were issued by the United
States Patent Office in January&nbsp;1993. Subsequent to the commencement of Milestone&#146;s action for a
Declaratory Judgment, Dr.&nbsp;Hodosh commenced a patent infringement suit in the United States District
Court for the Southern District of New York. Milestone has received opinions from patent counsel,
not involved in the litigations, to the effect that neither the <I>STA</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP> system nor the
<I>Compudent</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP> system infringe any of the claims of Dr.&nbsp;Hodosh&#146;s patents. Milestone
believes that it has meritorious defenses to Dr.&nbsp;Hodosh&#146;s action and it intends to vigorously
defend this law suit. Issue has not yet been joined in either action and Milestone&#146;s counsel is
considering whether or not it will seek to consolidate these actions which, essentially, deal with
the same subject matter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About Milestone Scientific, Inc.</B><BR>
Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering
proprietary, highly innovative technological solutions for the medical and dental markets. Central
to the Company&#146;s IP platform and product development strategy is its patented
<I>CompuFlo</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></SUP> technology for the improved delivery of local anesthetic below a
patient&#146;s threshold of pain. Specifically, <I>CompuFlo </I>is a computer-controlled, pressure sensitive
infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of
pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide
array of fluids. The STA&#153; System, a computer-controlled local anesthesia delivery (CCLAD)&nbsp;system
which uses this technology provides dentists with audible and visual signals as to in-tissue
pressure. Milestone&#146;s existing injection systems are currently sold in 25 countries. For more
information on these and other innovative Milestone products, please visit the Company&#146;s web site
found at <u>www.milesci.com</u>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B><I>Safe Harbor Statement</I></B><BR>
This press release contains forward-looking statements regarding the timing and financial impact of
the Milestone&#146;s ability to implement its business plan, expected revenues and future success. These
statements involve a number of risks and uncertainties and are based on assumptions involving
judgments with respect to future economic, competitive and market conditions and future business
decisions, all of which are difficult or impossible to predict accurately and many of which are
beyond Milestone&#146;s control. Some of the important factors that could cause actual results to differ
materially from those indicated by the forward-looking statements are general economic conditions,
failure to achieve expected revenue growth, changes in our operating expenses, adverse patent
rulings, FDA or legal developments, competitive pressures, changes in customer and market
requirements and standards, and the risk factors detailed from time to time in Milestone&#146;s periodic
filings with the Securities and Exchange Commission, including without limitation, Milestone&#146;s
Annual Report on Form 10-KSB for the year ended December&nbsp;31, 2006. The forward looking-statements
in this press release are based upon management&#146;s reasonable belief as of the date hereof.
Milestone undertakes no obligation to revise or update publicly any forward-looking statements for
any reason.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FOR MORE INFORMATION, PLEASE CONTACT:<BR>
Elite Financial Communications Group, LLC<BR>
Dodi Handy, President and CEO, or Daniel Conway, Chief Strategist<BR>
407-585-1080 or via email at mlss@efcg.net</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio --><!-- /Folio -->
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y39605y3960501.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y39605y3960501.gif
M1TE&.#EA\``W`/<``````(````"``("`````@(``@`"`@,&_O\#<P*;*\!@I
M0B,G/R0N4B0X:R<N2RHR7RDT42Q`<2E"A"XN1BTR4#$X5#,Y7RT\;#`[<S-`
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MG]Z;K]R\R-G#U-S'X-O3QMG3U-W;SMW;U]_=WN#?ZN#EX.3F[>ARB^AVE.6`
ME.B#F^6,F.>-I>28I>6:J^>:M^*CO>*OKN2OONBRS."ZT^#+SN7+U./6U>74
MW^;@W^CFXN?GWN^!E>^"H/",H^V>K.^<NO*HM/&NON_'TN_N[?/]]_1YF/9_
ME_F#IO:]Q_?)S_?5V//OY_?OY_CW]_?W]_OU\/[^_OS\]*&>HW]]A/\```#_
M`/__````__\`_P#______R'Y!```````+`````#P`#<`AP```(````"``("`
M````@(``@`"`@,&_O\#<P*;*\!@I0B,G/R0N4B0X:R<N2RHR7RDT42Q`<2E"
MA"XN1BTR4#$X5#,Y7RT\;#`[<S-`8S5+@#@[4CA!<CQ*=3A-C$-#5D!#84%&
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MU]_=WN#?ZN#EX.3F[>ARB^AVE.6`E.B#F^6,F.>-I>28I>6:J^>:M^*CO>*O
MKN2OONBRS."ZT^#+SN7+U./6U>74W^;@W^CFXN?GWN^!E>^"H/",H^V>K.^<
MNO*HM/&NON_'TN_N[?/]]_1YF/9_E_F#IO:]Q_?)S_?5V//OY_?OY_CW]_?W
M]_OU\/[^_OS\]*&>HW]]A/\```#_`/__````__\`_P#______PC^`.L)K">O
MH,&"!`<J7,A0H<%T".4E;$BQHL6+&#-JW,BQ8;J.($-RE(CL29(O*+$D44(F
MF4AYZ.HD64*FS)4A.@2)W,FSI\^?0(-6M.?M"0<.,)(F=>%&8D=[\E;Y4`'#
MA@@..IX<<RJTJ]>O8,->1-?-F"`='&S`>`%#19)57#7"_/+"A@T5(,3D,F8,
MG=B_@'U^#"P49BY4@8BD4%OU!1F$&NVA6V6$+0P2332=ZDNXLV>&,)4=ZX9.
MWN#//"6B0W?L5!^[2F$8V;H1GC<W-:K"$"%&55^G]E`+_PI3EZI,@@35$12(
MD2Q@V^@-WPFSVRDCN9/:T.'(KT9TK(;^,(:1PL^QTM/3"T6G2E";-W;L-+*4
M2=(E5ZT^S=H65WU&F,94H1UC2M"&D3S>T*4"8RG\X<U$H(T44G#]@<15<)W!
M=$HHBBS2R"6RF&(**-!(XD@OK[PBBB"0((.A?_6<1A$ZQI`QH&YM5`@:.L0,
MP19C)=3A74,Z-O2B5T4N)-&1/3$9H4#HS)*()ZWPX@PLU$"R22V70&)*,]"8
MP@HD=DCBDD`Z.BE2<$<6Z68W9:C%F%I)**.F0^BX,:==)`B9I#W255005)`E
M::1!`]U)9'"KH3=07!1"11`]$CFU)#P'#=J0-Z%X4DDSO/0"C"JJF`+)*(\4
M8@HXU+#2R2#^A$`B"3$2?11HI9#5X^2%;$H$#X8'V2.I0I+20V%#9,59%55J
M[>"(H9(1\P.S=ME0`AO>J1:&$4F4488;;GR1A1%CH(<.%D9DX:T;WR9AQ`&&
MKF*2%V60T<87[&:!1155+%&&N$OH<B2%RMBQPPLOU)"$(,J@HXPF7-%C1Q;J
M>KLNN&2`ZX8=%O][128,P2,*(J_XTHPSI4Q2"#7B9()')(1L8LHJN^PR2"2K
M,`**-@BA8Y*W*'VQ"I$$L6'$%6ZTP6X23B!#4!L^9($2&5]\^P466221Q!5>
M4-P4LMV0<9<(53&&A3=,1AR3#1Q0I9L*:_CE%'MC@)`652I<8`3^7`7%E(,%
M*2@E`@UM;,557/(@,P8+%I#@-@D/<'#""2QD8`%2&K3AY"X_/)`#&WY`@0(&
M.RRQ0PO(+(F.$I>)T$`$%V#0`=XPF)`!!A=<$($&)JB0Q>'HU))(R;Z(P\XT
MICP"#3CB"!)))(,44D@DK!0R2"VO+**(-WVW@4(&"ZJ@PA+*Y(JF/*H\`4((
M5'%`0W>KJ>+#42H@#`,'%H!P`@H@9'"!XSO@'D/(,@8;D(`#@6/,#E21)'KH
M0@DCH$%NJF6"N%D*'<@P1BIRL*"[)*$8OUF-,7+!!A9H9P1C*(8W'`4:;WA#
M%58@VUI&@`5-I$(5IT!%&WJ0`@^0`5/^CZ),"*QP"V*HXA:I*$('`J>"5?@%
M'<50`EYX@`4K6`$+BEE6"O!Q12M4`0<G<$$5T&.:;%3B%="(QCC*P49K3$,<
MX`C'*`:Q"4(0PA"1V`3,:M&,#S&B4=X@!CY(D!05U(`,:(,03(YQ#%/@8`0F
M0,$M2`,/>'3C&)KH@0C44@(:U`&'J;A%(+"``A'4@#,+(8N-2)`#%"Q(.VT8
MDI+080<;5.`)/E"*M<K%%8<1(Q4%5(L84[%"@J#CA:=X`H/84`P6[N@8J=!$
M$FI@%QKXX12W(%4T,V$$#6`!B`11QA<Z:4-BZ`*)IQ@#"L@C"*CP:`@<L`(I
M,$&*>?K!!W;^<4$.,'$`36`B$YB(81+.0Y!N=.H5SC#'.Q;:CG*(0QS4<,0@
MZ)A'ZJW"5)+(Q"@J(0=@H",9QE!%(VKPRH2YP5%S>^$M&M'-'$RR-*LA!BKN
MV1@CG`*;J;AI)MBPF%3($DK=R,)NB$`$9E7%!ZGHCVJ.D00/$($.1AB0"L0@
M0(&XLQAUV$$AL?";@9#E%@5$F`CJ0!HES=(8J!!#=FK0"%TD(QD?)<8MWA`!
M)X`3':;8@0ETH`H5KN88JM!$$!PG".ZQYP4C.``J<I&+<QX@EY?QP6*)80R9
M'L`&*4@%/593"Y(YHQKN@,=JNF&.<@0#$C`SQ"8VH256L,(6OX#^QI4\<8A*
MK)!&J8!"M9J%2,0=<QNGR((&C-!,B!3$&[DX@!.2\H(B$&,;WE`&2&^!"B>(
M0!7.)(@QA"H"*JBA!5+]`CC/!P]'[`80?3#"G%1P-J5ZXP\[L,M4JXHF&HFM
M+B+X0W:)1*-@&O(`W%,-:TQQ@UA2R!MMN(L1=%$:@T"S#R](06%AXH8/6,$W
MC4K&*>);.Q\8X[;>`"P6<,!@>B0#%)YXA32L\0YTT`,>[S@'-Y3!B>EM8DR=
MN/$NJ+&,933C%9_0`Q\\BB!MK,$&&AB!+@U\UC%H(`G%?)0W4I$$V#B!-`:Q
M#3'H0`0&#W"[N[D'(WQ`-M@,]*?R.$;^%CB0`TT<H,IE8R]]T>2-1L3W+E15
M:MAL@-]&[!=9QO!O#30A2YB`\#<%289089`$7<!#(:RY11(X4(?;_L$*FHAR
M/=!QBB$DQ00^6&%*5>%6=,!#%8EHA3.D88[0PI@TRE#&+O2X6BUM@A/!F`8T
M>L$,9_`B$6'P`SK2P1H_V&`$*TB+G$Z*(0S95P-/F#-,J%Q(*`])(F71A::]
M"N;RG$(,@6N,#>S0'WCH*01LB&82="EG]]I9OGE6DC?NNQL_&^I1W0@F#&J0
MB0<)A%*0Z(8+*\6:=:^%#'S[-XU**`C1?M08QZ`O.F[AZ<AJNCJWY30B6O&,
M<9BC'>_HALC^':8,9-!ZM9OHA"G4`0TMC4(4L%#$'.9P'GETPP\P0($::$!(
MM0SA67%1);3'"R5)JT4%T7[T0':A"F\D8\Y0,L82R/.'6QS`"-1BM"YZV8TE
MD*`'H4Q%%=9;!:@CR,[+BK=#YLWGW>CWWFC:LUKX349Y/,('#"Z4-Y)``CGM
MX`N[(*,WC*$+1+N0OAJJ.`E"C69,??0`GVC&,Z#Q<7=P@^2RGG4>:;V+8/2B
M%J;`!B<@(0@ZI`$-V1!M-QJ1\S[<XP1]3\H0G`CI&@V]/^B@M@?A:E5T)*%<
M?^;1ND60"6.`-8%V>4$L!P(/3>P``_?(13>((2#MJ*#L[M8JGLW^SG:VY/?/
MH#F&V.Z"5'10Z!A#J`$##]>-/]#`,G79@1+L4!K;W%97B'K4Q!7/>(JDV0^A
MT`NK!@F[T`TS5G(UHWEY=#.;``SB``V]-@J2T`AT$`9[4`NKD0QU8`,M`%!T
M0`,=H!M#P$!>%39/1G2;1FUM47;&(AF"4`-58#Z01@S#!V#&$`@T\$IK`64.
MA@7N@PH"1PQ88!EW$6W9EW;<1V\B8&__L6<D-03+H0ID,G8M0&B'@UQ/$`*+
M<1=M(7]VX&BB91$P<0M:97$_Y57$T`B-,`O.8`UFL`O*0`S:@`R[D&,I5T>T
MM@IPU`SK$`[.T`NPD`A[L`>8L$+>(`C^-D`#MW`+IW`/*$`"VC>"PK)I)I@$
M*)A[5<86"^,(I.(&.^`6VS:#3J`"B>5"N6`%(U`7;.$L!0$/+S@"?O!A_649
M,%`"3L!]=E87\^5>2LB$!Y)OU)04*2`"5R$"B_$"!_!34'0`6'`"&%`_-1"-
M]6,$)&@HG*95+T`".A!EN$<,?R`)I``-M>`(PK`+JP`,W"`,KG)C)[<)O^`,
MX;`.Z]`,S<`,O(`(>H`&!T`:AZ@"-"!]F$0')Q`"1[=@?6."3W")5&8_)3`"
M&O"03)0$J#1`Q.`$)C`"F2!"!T!2]O,"9W-,9$`"1(`*YS&+;=$6M^A>\%47
M)=!>\F8CWO?^=DU(!@F#6""``B@P`B@P.\B(9MYP"YAP#RO0`2/0<VQ1`D-@
M"MZA)F.(C=H(=?5%#'7@")I@#=0@#=?`";O`"KM@"IS0":XU:ZSE".`01\T@
M#LT`#D"&CV?0"'!59RJ0`L0`#Z*!"6%P`E11%U>0.D*7D+A'92Y`4B%`.2RP
M`B/0`220!-V@(S!!@RF``E8X93&$,"]@2([P0COP`&&0"S!E#/=0`Y7Y`B5@
M!&:'#B,5C2G@DFM'DPC3`3)Y(,<P!@E3`BQ`!P=P"O,4!BT@`I?)$/2`3(UP
M#_BP`160`GFI`@ND*#`A/V+5`Z'H52+%(JXU"KV@"KN@E76X"Y/^H&.;(`F_
MH`[.$)Y^^&.?@`AY<`:7\):-\`(L$$*Z0`IA4)QLX0)9@`Q0Y&2D^9=/4#\I
MT`.8<`HY!0A"P`$2>8;&I`I&(`(H<`J=V0@MD`*4Z9%!Q0$SL!E/9`QL`)K\
M:02+.4LCA3"IF80(HP(=(&R6\B0%)9L11@-]$$JWD`D'4`0@X&=*HAK=8'44
M6`0S4`$<`*)CD"0:X@-BQ0//"26YT`@LLEIQ4`NC8@VV$`R<X%JLH)4Y-@WJ
M4);@L`[.0)YZ<`9G0`J&N)[M*3<\D@E0``(B@#`M4`49)`818(FX=PO[&6%!
M@`JID%.8X`<H$`03B2>I0&8H@%T$\4+^19"*+8`P/L`&.Q`"]V`,RH`FQ^`'
MH/D"#UH$?6I,'_J@JBEE:S"B'&"B9@4:@0:B--`(LG@,)+0"R=@?R%`^QW2C
MIX`)C8`/)P`"*9`"10!^TZ8#K4FD!KIIQH"DCK!:=[`*N<8,R\`.M>`JG+`)
M=5@(JQ`.92D.ZZ"6L&">9X`&IV"(?_"8J"0/RF`,FM`$MDJI-(`%JC`&'&"$
MJ70+3@"AN%H,_!A21>"<^S5M/M`!@4JFQM`'*`"O*/`"-,`!*)`*QF`IP?J@
M+;";/7"I,#%2"YL":B=ELGFK'&!O<'=,X/:@-)!IA%(6FA!Q"X$,05`%^C=]
ML>H',C`"_4G^4/R5"CKPH!W@JS-R#`?P!X*P"IL0!YV@"]-0K6GY"Z8`EC7C
M*J8`#>H0#K(%9'IPGFF`76?GK=<V<0=@!180ERE``V-`!G6ED.\ZC$409:QQ
M0T6*K_I*#-G2#:B0`QSPH/^:`A9`!"KT*,9P`#1PJRR0`CG05?HW4BG0`C3$
M?6-PJRF0`;[H?V@2:'\[`BR0D0078MV@=`0!$SG@`RCU5]%D!:74`RZ[(QMT
MJQV``T4ZJ)K@!X(@"3O;@.+@#%BZ#M/`E5PY:ZPP"K;@"(X@"N79I5O0!WUQ
M3(T@M9#F#;$J!!E`N#D0!!?0!&$(::E@!(\Y`F&;+33B#1VZ(Z?^H`,**JC&
M5`QB``(Z^:^,>P`3:7,;R;(Y20-)A3AU=K<Y.;%T-KC_F@&@ZA`$`06J@&_@
ME@*,VV\1`1-/9`4/<DPYT`*"0$;&1".9H`,CT`-EQ5^GD`.@*[J_FH)^8+J.
M``>10`Y96JW,$$?4$`RZ`)8WM@JL`#V74`EZ(`=1T`4'L!6KH:<G<*G'9'4]
M``'_BI,<4`0*:00X&0+1JW_HX0AL,$N:`,$H0*-`=0H]\+TI``%-\&$.T0T'
MD`/?BY-^8#YG1P,X.0+N.ZAK@)-P.[\.X085H`F/<@R.F),L8(6/8DQ5,`.&
M510@,!NXUPV:8`09H!6_.FVMM),27!'^K'$`=%`'=N`&A6`+SP`.\%B6ZP">
MOU".*+<)@P`'=9`&Y[D%:N!3?>,'*7`"/C5`4Q8(.)`!:IP!.ARG/+R3/_PH
M!:$*-"`&ZFNW.GD/+(0.PV`4.-D!$.`'M!+%4US%)W`/6(P.=KO%78P@7XR3
M%B#&:'(`*+`!7D80:+S%:WR&\D`'(1`$@,0&(8`"8@`A4&*W#,`&EZI_JJ`#
M.;G`G6N]=,`&;4`&5"E;SJ`.S^`,';P.RV`+.58(K&4';=`&:;`%48`&I'"P
M!14(+W`"A(8L&H8),V`!.&G*TH8.N9#*'4`$SXD.36`!!6Q5`J$*1(`"^U,$
M3G/&@?`!6@C^`4=`#-7[;\JP.,!<!.7S(J*5"3FP/R?PD?*F3B(P`B?P!\`1
M'+HP!C1``4_0,''G!C@]`\]R)*J`!2S``%;08-Z@"2P008Z0*`*1#D]``3G0
M=">Z$/2@"E2,DSP`%V@":`?`!O>`!6\@"##'"_1HS\L`#KU`#*ZU"K;;!F,P
M!F`0!5.P"`Q:*?!`!CA);KO"&J4K`QL`MT308/JW"DV`TW2<*#$Q!"'P`4TW
M$,A0!T9P`B.@DR=@!'7@90B2"T]0`2```N(+V02A"U@P`_L3VCB)`J0=S?6@
M#*24D[9]OXIT##**DR?P!(U@N_Y<!3D``@RP`IE&1I1!.92#!7_^H`G)009)
MD-P0H-"BQAX]0`$5@`)CL`H-0\Q&0`$KD`J<>3B0I@I0,-LZ^000(RCLX0?W
M\`1C4`<`^`DI\@J@L@RRH`J2``F.H!QC@`50P`12H`86JAIU`$8H4`22X'^L
MH0I]L`(@0`&/K52"X.`HH+6"0-UN@`4]P#A&#<7U@`PX0`$4``$.0`$.X``5
ML`$;8+(`D@DKL`!$`-:/P@8@4`$58`$L[N+>39P;,,3RX`@I[@`,H.(4``(]
M`,!H(@8H``%4SN(0$.,_[MT.L``LT`@LK1I/\`%6S@`,0.4^[N,6L.4XH`FY
M($`TX@>3O0`+``(S0`,L0`$+T`2I@`K^4$D05O`!&R#D+:[B'_`!3^`F4]8'
M5H0%8T`'4_()D.X)GK`(R2$(;\#74/`$3>!=F9#>]:`*,Q#H+>X`'[`"3V#-
M8\L&-WX$SB0(/?`!+PX!9'[E/U[E<GYAG)$X8O`$3T`$1R`$1]`$P@[?<E,6
M;-`$+7QM\G``FHX/0O#L0@`$1T`$3?`$%];*5J#IP![LUD[+D\L&S7X$1X`/
MO%[NS6X%!W`+7:4,NTX%SD[M36!%O"[L31`&Z5Z]QT0,,,H&5H`/1"`$35`%
MC7!$+>T0\E`'V?X$^/#KX\[K5N`G,V+'?B`&5@`%8H`&AZ`'&L\'<[`&;,`&
M?8T%YWX/!Z#^;94"0\V.#^1N!71PK[A%!T(@QO*@"0G_[L-N[KQ^#YL!1`BB
M09CP\XSP\_\I?0\B#_`04KZ!>/GN3XS`"'W0!TW_\Q9JB,80JT)/"JIP#`VC
M&H$4JT$O]3>%F_6$3=_J,*HP3U__GS?E9E*O[K)$(\00]CBUB`9;<X@#)=[@
M6#_?"%]/:J(&SO75&GT0!E:T!5[JI6"`!8I?14]0!"M/\F#=-R'&]E(?<7T.
M(+[!MYM&O:EP`)C`"(U`3SF%FU*?"FB+*[^U#<2P^D9$61$7$:\:BHM$#+E`
M*K9_I[>0"W;/&KIP#*T_0HBV^<:A"\.O"[E`6<:W^KV;UF31#<;^P5C0GPO%
M4`R,!7'[M1HA=@S#/T)89A''I/VZ8$[*OQ?++]\:1(%AP`51H`51$`7^W@34
MS@1$P$7WT`>=?G$T`G&JL!?'8)]`&OL`@:[>P'KRT'7;MDV5+H:Y'.8B9BR7
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M@532195C,-)E%4V00::_]C`ZAD&C@E-%M?[N<ZFP]OZ2YX]['COP/!%''$B]
MA301`P=OXI*G*TT*9`.'1C#R!H<FF)*GC0_8T,24`^XY(L2!T`'B`RSJL<>C
M)U9`AB`_K*A#$R%X.""0)\3XZ!X0V/A(%QS$T$0U.HX(XZ-C<'A"N8'H(*(U
M552Q`@AE2*3^4SM=5FA$HV[\\&8D(62H)R4<N"3)&QZ"L"G).BC0)"555@1)
MGB:"`.&/D/X0@CI5E'FJAQLLLD^E>S:H0Z5C8F#C*8N.T20D>6I\@JEZ5-D@
MSXT:D6'..G==+D<*ZDB2GIXNDD>3#^SPIB=ONCG)HZ=R"&*IH=K8X("E*HO-
M(GP$*6(#1^2!)Q,KEC(I%R)F,`T=F`)%1TLR1$+'F"\Y@HVM8WIP8BR#B.CA
MU9ZZ04967@?VS"!58H@AB";`],DC<)]@(95F2[()'GFC7<D;-BP0HQ%!8M0%
M1W2:\",7(3[(!!U-QG75(F."0'=B=L?8(-65<KG!B48.:`0?/PS^8LL8'II8
M,2-35F#C&'AP6HI@ISLSJ)MC&A'CY`F,"/%5'$[(!=)(X36&AB(L*DCC7T_+
M!(>0,1I9$%14Z0&$"JT`&B1TDND!W0$'H@>=,2JPV:!<9L`B%P.M(#3HH:45
M8TO+TGHZ<LZ>>L@T*RA(L[0B0&@4K<*@7>I5-BKX`]MD@T+GB4:\2465%6+X
M0PSC`O7&4\M$$I;FP+T97(QD"ZL(7ET4;A:=1C9XXG8U,9*\>;_N,\VA8SZX
MT:!C'`$A<X("W/Z8((@(R:(Z2)7)HV-L\DF,1Y/)19,55FC".,UY()L@F-@`
M88P!`^0!BV1[LHE!AO>$AGGC7BM0Q4C^,.0\!LK%()-R!#)8]80GZ*)9%,$"
M#L)0$67\X0A_V(T\5`$"&11-'MUX@@.L$*9,_($(="L4#Y)WD`IM8`6RRD@J
M5O`!5<1%6$U089(RTH@/]"!XLU/9!U2TDF,(`@=":`1-5E&U`WVG@5<TB#'&
MX`0V^$$,=0A.P^)U##B)P4,KU)<\#H`#(J0B),1X@HW",`8K-$$(JPB@)HC0
MA&X8I!BY8`,!IX..0`BA!YW#B#&L@(,U]"E0=&#CVLC2B!X<X3X9,>`QGG2/
M.EC!=P*[8BA+<Y+?':1^P%F510!8FF1P"B<1ZH887Y61H?@D=/"0FBO9Y@UE
M*.-Q)#D(,II$9LIZT8>7QS#A4\*HJIJ$TIEI:4NS4*<J:J(#+ZJ49MF"HZRF
BL>4I\+!;3VYRMV3]Y2F_*]3O0F.16,8F2<HB9?WR$A``.S\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
